Online inquiry

IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7779MR)

This product GTTS-WQ7779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MMP9 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_004994.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4318
UniProt ID P14780
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7779MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3596MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ14466MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ3164MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ9154MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ5737MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ6356MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ3592MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ15015MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW